GoodRx Holdings, Inc. (GDRX) Fair Value 2026

GDRX · Health Information Services ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.1 /10

32 fundamental signals · 10 models active

Value Trap Risk

LOW (29/100)

Quick Summary — As of 2026-08-27, GoodRx Holdings, Inc. (GDRX) trades at $3.51, versus a $7.39 median fair value across its 10 active models — 110.7% above the current price. QOC: 8.1/10. Value Trap Risk: 29/100 (LOW). 10/13 models active. Within that set, the Bayesian DCF component alone returns $7.64.

Key Facts

Ticker
GDRX
Price
$3.51
Quality Score
8.1/10
Value Trap Risk
29/100
Models Active
10/13
Last Updated
Strength: First Chicago suggests +253.6% upside with 59% confidence
Risk: Limited model coverage (10/13) may reduce confidence

Is GoodRx Holdings, Inc. (GDRX) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, GoodRx Holdings, Inc. (GDRX) appears undervalued as of : the median of 10 independent fair value estimates is $7.39, 110.7% above the current price of $3.51. Estimates range from $1.32 to $13.93. GDRX scores 8.1/10 on fundamental quality and 29/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. GDRX’s +110.7% gap is wider than that market norm, and the Health Information Services sector median is +4.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy GoodRx Holdings, Inc. Stock in 2026? →

What Fair Value Does Each Model Give GDRX?

10 Intrinsic Value Models vs. Current Price ($3.51)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $7.64 +117.7%
Ensemble · Low Conviction
 $7.15 +103.6%
Scenario · High Conviction
 $12.41 +253.6%
Intrinsic · High Conviction
 $1.76 -50.0%
Unlock the Full Matrix

Access 6 additional models including Markov DDM, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is GDRX's Fair Value Range?

Spread across 10 independent models · $1.32 to $13.93

CirclFi's 10 active models place GoodRx Holdings, Inc. (GDRX) between $1.32 and $13.93 per share, a spread of 171% of the median. The median of that range — $7.39 — is the fair value CirclFi publishes for GDRX, against a current price of $3.51.

Low · Markov DDMHigh · Regime Cross
$1.32median $7.39$13.93
Where the range comes from
Most bearish modelMarkov DDM$1.32
Most bullish modelRegime Cross-Sectional$13.93
Model agreement8 bullish · 2 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for GDRX. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on GDRX, not a CirclFi price target. How each model works →

What Is GoodRx Holdings, Inc. (GDRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for GoodRx Holdings, Inc.. Trading at $3.51 against an estimated intrinsic value of $7.39, 8 of 10 active models flag meaningful upside of +110.7% at the median. The most optimistic model, Regime Cross, places fair value at $13.93 (+296.9%), while Markov DDM — the most conservative — estimates $1.32 (-62.4%). This +359.4% gap reflects genuine analytical uncertainty about GoodRx Holdings, Inc.'s intrinsic worth.

What Do the Models Say About GDRX?

10 of 13 models are currently active for GDRX. Of these, 8 models suggest upside while 2 models suggest overvaluation. Taken together, their median fair value for GDRX is $7.39 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $7.64 on its own, implying +117.7% upside from the current price. See which stocks rank higher →

How Does GDRX Rank in Health Information Services?

Among 55 Health Information Services stocks, GDRX ranks #10 by Quality of Company score. CirclFi's QOC score of 8.1/10 evaluates 32 fundamental signals. A score of 8.1 places GDRX in the top tier.

See all Most Undervalued Health Information Services Stocks →

GoodRx Holdings, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is GDRX a Value Trap?

CirclFi's Value Trap algorithm assigns GDRX a score of 29/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for GoodRx Holdings, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, GoodRx Holdings, Inc.'s fundamental quality profile registers 8.1/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +359.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GDRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across GDRX's 10 active models, average confidence is 45%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy GoodRx Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Health Information Services Stocks Should You Also Analyze?

11 related Health Information Services stocks with 13-model coverage

OPRXOptimizeRx CorporationQOC 8.3PRVAPrivia Health Group, Inc.QOC 7.9CCLDCareCloud, Inc.QOC 8.4WAYWaystar Holding Corp.QOC 7.7PHRPhreesia, Inc.QOC 8.4TXG10x Genomics, Inc.QOC 7.6TALKTalkspace IncQOC 7.0EVHEvolent Health, Inc.QOC 5.8HCTIHealthcare Triangle, Inc.QOC 4.1DOCSDoximity, Inc.QOC 9.6HQYHealthEquity, Inc.QOC 9.5

Read investment analysis: OPRX · PRVA · CCLD · WAY · PHR · TXG · TALK · EVH · HCTI · DOCS · HQY

Which Other Stocks Have a Similar Quality Score to GDRX?

7 companies across all industries closest to GDRX’s Quality of Company score of 8.1/10.

SHCSotera Health CompanyQOC 8.1HUBGHub Group, Inc.QOC 8.1NPBNorthpointe Bancshares, Inc.QOC 8.1AIRAAR Corp.QOC 8.1FIGSFIGS, Inc.QOC 8.1MFAMFA Financial, Inc.QOC 8.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SHC · HUBG · NPB · AIR · FIGS · MFA · NVDA

Where Does GDRX Sit in CirclFi's Health Information Services Rankings?

GDRX is ranked against every other Health Information Services stock CirclFi covers in each of these screens.

See all Health Information Services stocks ranked →

What Else Do Investors Ask About GoodRx Holdings, Inc.’s Valuation?

What is GoodRx Holdings, Inc.'s intrinsic value in 2026?

CirclFi puts GoodRx Holdings, Inc. (GDRX)'s intrinsic value at $7.39 — the median of 10 independent model estimates as of 2026-08-27, ranging from $1.32 to $13.93. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $7.64 on its own. The Quality of Company score is 8.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GDRX overvalued or undervalued right now?

At $3.51, 8 of 10 active models suggest GDRX may be undervalued, while 2 indicate potential overvaluation. The median of all 10 fair value estimates is $7.39, 110.7% above the current price of $3.51 — a consensus view that GDRX is undervalued. The assessment depends on which methodology best fits GoodRx Holdings, Inc.'s business model in Health Information Services.

What does a Quality of Company score of 8.1 mean for GDRX?

GoodRx Holdings, Inc.'s QOC of 8.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on GDRX?

CirclFi analyzes GDRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on GDRX?

Of the 10 models currently active on GDRX, Regime Cross-Sectional is the most bullish at $13.93 per share, and Markov DDM is the most bearish at $1.32. CirclFi's published fair value for GDRX is the median of that range, $7.39, not either extreme. The gap between the two ends equals 171% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is GDRX a value trap in 2026?

GoodRx Holdings, Inc.'s Value Trap score is 29/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 10-model valuation engine, GoodRx Holdings, Inc. (GDRX) has a median fair value of $7.39 — 110.7% above the current price of $3.51 — as of 2026-08-27.” Source: circlfi.com/stock/GDRX/ · Methodology
Primary sources for this GDRX valuation
  • Financial statements: GoodRx Holdings, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001809519) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GDRX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on GDRX.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

6 models hidden for GDRX Unlock All 10 — $39/mo